In the hereditary disease hereditary angioedema (HAE), swellings occur in one or more parts of the body without a recognisable trigger. Especially if the upper respiratory tract is affected, a so-called HAE attack can be life-threatening. Active substances for on-demand medication are so far only available in the form of injections and infusions. In a phase 2 study led by the University Hospital Frankfurt and the Charité – Universitätsmedizin Berlin, it has now been shown for the first time that an orally administered active substance is effective. The therapy could replace the much more time-consuming and stressful injections.
For more information, please see the official press release and the abstract to the paper below.
Press Release Universitätsklinikum Frankfurt
Aygören-Pürsün E, Zanichelli A, Cohn DM, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Farkas H, Kiani-Alikhan S, Grivcheva-Panovska V, Bernstein JA, Li HH, Longhurst HJ, Audhya PK, Smith MD, Yea CM, Maetzel A, Lee DK, Feener EP, Gower R, Lumry WR, Banerji A, Riedl MA, Maurer M. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet. 2023 Feb 11;401(10375):458-469. doi: 10.1016/S0140-6736(22)02406-0. PMID: 36774155.
Read more news from ACARE
- March 2, 2023
The HAE Relay: Expert Exchange video series is designed to provide engaging and informative bite-size content to healthcare professionals who are either new to hereditary angioedema (HAE), or are established [...]
- September 1, 2023
Welcome to our second episode of the All Things Angioedema - Learning about Angioedema with Dr. Thomas Buttgereit Podcast Dr Thomas Buttgereit is joined by Professor Markus Magerl, leader of [...]
- July 28, 2023
A very warm welcome to Clínica Universidad de Navarra, who has joined the ACARE network on July 13, 2023. Head: Marta Ferrer Auditor: Ana M Giménez-Arnau This makes it our [...]